8:00 am Coffee & Registration

8:45 am Chair’s Opening Remarks

Optimising TCR-based Therapies

9:00 am Antibody Redirected TCR T-Cell Therapy for the Treatment of Solid Tumors

• Cheng Liu Chief Executive Officer, Eureka Therapeutics

9:30 am Engaging the Full T Cell Receptor Freed of HLA Dependence

• Robert Hofmeister Chief Scientific Officer, TCR2

10:00 am Morning Refreshments & Speed Networking

11:30 am Drugging Undruggable Cancer Targets with TCR Mimic Antibodies

• David Scheinberg Chairman, Molecular Pharmacology, Memorial Sloan Kettering Cancer Center

12:00 pm Allogeneic vs Autologous Settings: A Quest for TCR-T Market Penetration

• Steffen Walter Chief Scientific Officer, Immatics US

Strategy to Expand Patient Populations

1:00 pm Lunch & Networking

1:30 pm Developing MHC Class II Restricted TCRs for Action in Solid Tumor Settings

• Gang Zeng Chief Executive Officer, T-Cure Biosciences Inc.

2:00 pm Transcriptional Profiling and TCR Clonotypes to Gain Translational Insights for a Pre-Manufactured, Clinical Stage Allogenic T-Cell Immunotherapy

• Blake Aftab Head of Preclinical and Translational Sciences, Atara Biotherapeutics Inc.

2:30 pm Panel Discussion: Advancing Beyond HLA 201 – strategies for Delivery to a Wider Patient Population

• Blake Aftab Head of Preclinical and Translational Sciences, Atara Biotherapeutics Inc.
• Gang Zeng Chief Executive Officer, T-Cure Biosciences Inc.
• David Scheinberg Chairman, Molecular Pharmacology, Memorial Sloan Kettering Cancer Center
• David Berman Head of Research and Development, Immunocore

3:15 pm Afternoon Poster Session

Taking TCRs to the Clinic Safely

4:00 pm Clinical Validation of a Soluble Bispecific T cell Engager Platform

• David Berman Head of Research and Development, Immunocore

4:30 pm Accelerating TCR Therapy into the Clinic

• Dolores Schendel CEO, Medigene

5:00 pm Chair’s Closing Remarks

5:15 pm End of Day 1